← Leaderboards
Siddharth Singh
University Of California, San Diego
$3,185,616
Attributed
$4,685,612
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,435,618 · 3
CDC$2,249,994 · 1
By mechanism
U01$2,249,994 · 1
R01$1,262,607 · 1
K23$970,511 · 1
R03$202,500 · 1
Top collaborators
- Meenakshi Bewtra3 shared
- Michael D Kappelman3 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Maurice S Swanson$17,857,475
- Eugene Wei-Ming Yeo$40,192,855
- Hari Kope Narayan$589,773
- Adrienne R.s. Lee$134,690
- J. Silvio Gutkind$14,229,551
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyInnovationTreatment EffectivenessHigh RiskPrevalenceImmunomodulatorsOperative Surgical ProceduresTherapeutic ImmunosuppressionEvidence BaseCohortIncidenceInflammatory Bowel DiseasesComparative EffectivenessHospitalizationInfectionBaseCessation Of LifeDisorder RiskClinical InformaticsDatabasesIndividualized MedicineElderlyBurden Of IllnessCombined Modality Therapy
Grant awards (12)
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$774,997
U01 · FY2025 · DP
Comparative effectiveness research in Hispanic patients with inflammatory bowel diseases$591,209
R01 · FY2025 · DK · contact PI
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$774,997
U01 · FY2024 · DP
Comparative effectiveness research in Hispanic patients with inflammatory bowel diseases$671,398
R01 · FY2024 · DK · contact PI
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$700,000
U01 · FY2023 · DP
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases$169,210
K23 · FY2022 · DK · contact PI
Predicting Short- and Long-term Risk of Serious Infections in Older Patients with Inflammatory Bowel Diseases$94,000
R03 · FY2022 · DK · contact PI
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases$189,449
K23 · FY2021 · DK · contact PI
Predicting Short- and Long-term Risk of Serious Infections in Older Patients with Inflammatory Bowel Diseases$108,500
R03 · FY2021 · DK · contact PI
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases$203,990
K23 · FY2020 · DK · contact PI
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases$203,990
K23 · FY2019 · DK · contact PI
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases$203,872
K23 · FY2018 · DK · contact PI